Medical Expert Videos | mBC | KISQALI® (ribociclib) | HCP

Two women talking to medical expert

Medical expert video library

Hear from oncologists and medical experts about KISQALI^® (ribociclib) in hormone receptor-positive/ human epidermal growth factor receptor 2-negative (HR+/HER2-) metastatic breast cancer (mBC).

The health care providers and patients in the videos below have been compensated for their time by Novartis Pharmaceuticals Corporation.

MORE PERSPECTIVES

FA-11533062 KISQALI mBC MORE Faces of KISQALI Dr Mardones Vi

Mabel Mardones, MD, explains why overall survival is her gold standard

Dr Mardones discusses her approach to selecting a CDK4/6 inhibitor for patients with HR+/HER2− mBC, including why overall survival is her gold standard, and shares perspectives from her clinical practice in Colorado.

Learn more: View overall survival data from the MONALEESA clinical trials

AI, aromatase inhibitor; HER2-, human epidermal growth factor receptor 2-negative; HR+, hormone receptor-positive; mBC, metastatic breast cancer.

FA-11533075 KISQALI mBC MORE Faces of KISQALI Video - Dr Coh

Jules Cohen, MD, discusses why he chooses KISQALI first

How does Dr Cohen evaluate CDK4/6 inhibitors, including KISQALI, for patients with HR+/HER2- mBC? Watch as he reviews overall survival data from the 3 MONALEESA trials and shares his clinical perspective from treating patients in his New York practice.

Learn more: See the data making a difference in HR+/HER2- mBC

CDK, cyclin-dependent kinase.

FA-11561645 KISQALI mBC MORE Faces Dr Cohen Dr Mardones M7 V

The role of MONALEESA-7 in treating premenopausal patients with HR+/HER2- mBC

How do Drs Cohen and Mardones make treatment decisions for premenopausal patients with HR+/HER2- mBC? Watch as they review overall survival data from MONALEESA-7 and discuss their use of KISQALI for appropriate premenopausal patients with HR+/HER2- mBC.

Learn more: Explore data in premenopausal patients with HR+/HER2- mBC

Coming_Soon_Video.mp4

Chaitali Nangia, MD, on treating HR+/HER2- mBC, including visceral metastases

How does Dr Nangia decide when KISQALI may be an appropriate treatment for her patients with HR+/HER2- mBC, including those with visceral metastases? Watch to hear why she considers KISQALI.

Learn more: Explore KISQALI efficacy in aggressive and visceral disease

Real HCP & patient perspectives

Real HCP & patient perspectives on treatment with KISQALI

How do doctors and patients discuss treatments for HR+/HER2- mBC, and what are they saying about KISQALI? Watch as an oncologist and a patient sit down for a face-to-face conversation to share their experiences and insights.

NCCN GUIDELINES®

FA-11237695 KISQALI mBC OKE Dr Cohen NCCN Video 9.24

An expert discusses the National Comprehensive Cancer Network® (NCCN®) Category 1 Preferred 1L treatment options

There is controversy on the choice of CDK4/6 inhibitor as there are no head-to-head comparisons between the agents and there are some differences in the study populations in the phase III randomized studies.¹
NCCN makes no warranties of any kind whatsoever regarding their content, use, or application and disclaims any responsibility for their application or use in any way.¹
Category 1: Based upon high-level evidence (≥1 randomized phase III trials or high-quality, robust meta-analyses), there is uniform NCCN consensus (≥85% support of the Panel) that the intervention is appropriate.¹

1L, first line.

EFFICACY & SAFETY

Coming Soon Video_1.3 6

Gabriel Hortobagyi, MD, discusses KISQALI overall survival across 3 phase III trials

Dr Gabriel Hortobagyi discusses proven overall survival with KISQALI across 3 phase III trials.

Learn more: Explore data from the 3 phase III MONALEESA trials

DOSING

Coming_Soon_Video.mp4

Nick McAndrew, MD, shares insights on KISQALI dose adjustments

How does Dr McAndrew manage dose reductions of KISQALI when treating his patients with HR+/HER2- mBC?

Learn more: Explore KISQALI dosing and adjustments

Nick McAndrew, MD, discusses efficacy despite dose reduction

Nick McAndrew, MD, discusses efficacy and dose reductions

What data do Dr McAndrew rely on when choosing KISQALI for his patients with HR+/HER2- mBC?

Learn more: Explore efficacy data for KISQALI dose adjustments

ROUND TABLE

FA-11603284 KISQALI mBC ME ROUND TABLE VIDEO - QT AND ECG AS

Round table discussion: Managing QT interval and ECG assessments

How should doctors manage QT interval and ECG assessments when starting patients on KISQALI, and throughout their treatment? Watch as Drs Dent, Guha, and Moore discuss a hypothetical premenopausal patient with HR+/HER2- mBC.

Learn more: Explore KISQALI assessments and monitoring

FA-11604467 KISQALI MBC ME ROUND TABLE VIDEO - DR UG-DRUG IN

Round table discussion: Addressing DDIs

How should potential drug-drug interactions be addressed when patients on KISQALI are also taking medications for other conditions? Watch Drs Dent, Guha, and Moore discuss treatment management for a hypothetical postmenopausal patient with HR+/HER2- mBC.

FA-11603216 KISQALI mBC ME ROUND TABLE VIDEO - CARDI AC COMO

Round table discussion: Addressing cardiac comorbidities

How do cardiac comorbidities factor into treatment with KISQALI? Learn from Drs Dent, Guha, and Moore as they talk about hypothetical postmenopausal patient with preexisting cardiac conditions and discuss the best method for starting her on KISQALI.

DDI, drug-drug interaction; ECG, electrocardiogram.

< PREVIOUS: Local Insurance Coverage

VIDEOS, RESOURCES, & FAQs
NEXT: Resources >

Reference: 1. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines^®) for Breast Cancer V.6.2026. © National Comprehensive Cancer Network, Inc. 2026. All rights reserved. Accessed July 30, 2026. To view the most recent and complete version of the guideline, go online to NCCN.org